Entry Detail



General Information

Database ID:exR0089363
RNA Name:hsa-miR-92b-3p
RNA Type:miRNA
Chromosome:chr1
Starnd:+
Coordinate:
Start Site(bp):155195237End Site(bp):155195258
External Links:hsa-miR-92b-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE101841
Description:Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:Trastuzumab therapy
Case Disease Type:Breast Cancer
Case Disease SubType:HER2 positive metastatic breast cancer
Case Sample:Breast Cancer Trastuzumab resistant
Control Sample:Trastuzumab sensitive
Number of Case:42
Number of Control:61
Number of Samples:103





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ADCY3
chr2
24819169
24919839
-
ADCY9
chr16
3953387
4116442
-
ADM
chr11
10305073
10307397
+
CCDC186
chr10
114120862
114174232
-
FNBP4
chr11
47716494
47767443
-
KLF4
chr9
107484852
107490482
-
MRPS16
chr10
73248843
73252693
-
MTHFD2
chr2
74198610
74217565
+
NPTX1
chr17
80466834
80477843
-
NSMAF
chr8
58583508
58659853
-
PUS7
chr7
105439661
105522271
-
RBFOX2
chr22
35738736
36028824
-
SH3PXD2A
chr10
103594027
103855543
-
SOX4
chr6
21593751
21598619
+
XRN1
chr3
142306607
142448062
-
POLR2F
chr22
37952607
38041915
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001005
chr2
53921020
53978078
-
hsa_circ_0001414
chr4
56277780
56284152
+
hsa_circ_0000126
chr1
150997086
150999803
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC005394.2
chr19
28435388
28727680
-
AC074117.1
chr2
27356246
27367622
+
AC130650.2
chr16
14150833
14153235
+
DAPK1-IT1
chr9
87553454
87554459
+
LINC01128
chr1
825138
859446
+
MALAT1
chr11
65497688
65506516
+
NORAD
chr20
36045618
36051018
-
OIP5-AS1
chr15
41283990
41309737
+
PITPNA-AS1
chr17
1516931
1518096
+
PURPL
chr5
27217714
27496994
+
SNHG5
chr6
85650491
85678932
-
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE101841
Sample Source:Blood
Source Fraction:Serum
Platform:GPL23138
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1808
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:29691399
Title:A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:Nat Commun. 2018 Apr 24;9(1):1614.
Description:MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.